

A1390 JACC March 17, 2015 Volume 65, Issue 10S



IMPACT OF NEW BLOOD PRESSURE GUIDELINES ON THE USE OF ANTIHYPERTENSIVE THERAPY IN UNITED STATES

Poster Contributions Poster Hall B1 Saturday, March 14, 2015, 10:00 a.m.-10:45 a.m.

Session Title: Medical Management of Hypertension Abstract Category: 22. Prevention: Hypertension

Presentation Number: 1108-125


Authors: Vratika Agarwal, Neeraj Shah, Gregory Marcus, University Of California San Francisco, San Francisco, CA, USA

Background: Latest report from the Eighth Joint National Committee (JNC-8) has significantly liberalized blood pressure goals for treatment of hypertension, especially in elderly patients. We sought to determine potential impact of these new guidelines on the US population. Cohort: Participants in the 2011-2012 National Health & Nutrition Examination Survey (NHANES).

Methods: We selected NHANES participants >=18 years, who were not on antihypertensive therapy. We compared the proportions of participants eligible to receive antihypertensive therapy based on their current blood pressure, according to JNC-7 versus JNC-8 guidelines. We performed subgroup analyses in those with diabetes mellitus (DM), chronic kidney disease (CKD), & the elderly (≥60 years).

Results: The sample represented 171.4 million Americans with mean age of 41.9 ± 0.8 years & 49.8% females. The number of Americans eligible to receive antihypertensive therapy would decrease by 6.1 million, from 21.5 million (12.5%) per JNC-7 guidelines to 15.4 million (9.0%) per JNC-8 guidelines (Figure). In the elderly, number of eligible Americans would decrease from 8.2 million (31.0%) to 4.9 million (18.4%). Number of DM & CKD patients eligible to receive therapy would decrease by 3.2 million & 1.5 million, respectively.

Conclusion: Application of the new JNC-8 guidelines would decrease the number of US citizens eligible for antihypertensive therapy by 6.1 million, driven primarily by a substantial decrease amongst the elderly population.



Proportion of subjects eligible to receive antihypertensive therapy per old and new guidelines